Cargando…

Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis

The assurance of safety and effectiveness is a significant focal point in all therapeutic approaches. Although mesenchymal stem cells (MSCs) have been identified as a potential novel therapeutic strategy for multiple sclerosis (MS), existing evidence regarding the effectiveness and safety of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Islam, Md Asiful, Alam, Sayeda Sadia, Kundu, Shoumik, Ahmed, Saleh, Sultana, Shabiha, Patar, Azim, Hossan, Tareq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573670/
https://www.ncbi.nlm.nih.gov/pubmed/37834955
http://dx.doi.org/10.3390/jcm12196311
_version_ 1785120518288965632
author Islam, Md Asiful
Alam, Sayeda Sadia
Kundu, Shoumik
Ahmed, Saleh
Sultana, Shabiha
Patar, Azim
Hossan, Tareq
author_facet Islam, Md Asiful
Alam, Sayeda Sadia
Kundu, Shoumik
Ahmed, Saleh
Sultana, Shabiha
Patar, Azim
Hossan, Tareq
author_sort Islam, Md Asiful
collection PubMed
description The assurance of safety and effectiveness is a significant focal point in all therapeutic approaches. Although mesenchymal stem cells (MSCs) have been identified as a potential novel therapeutic strategy for multiple sclerosis (MS), existing evidence regarding the effectiveness and safety of this strategy remains inconclusive. Thus, the primary aim of this systematic review and meta-analysis (SRMA) was to comprehensively assess the effectiveness and safety of MSC therapy in individuals diagnosed with MS. A comprehensive search was conducted using appropriate keywords in the PubMed, Scopus, Cochrane, ScienceDirect, and Google Scholar databases to determine the eligible studies. The change in the expanded disability status scale (EDSS) score from baseline to follow-up was used to assess MSC efficacy. The effectiveness of the therapy was assessed using a random-effects model, which calculated the combined prevalence and 95% confidence intervals (CIs) for MS patients who experienced improvement, stability, or worsening of their condition. The protocol was registered in PROSPERO (CRD42020209671). The findings indicate that 40.4% (95% CI: 30.6–50.2) of MS patients exhibited improvements following MSC therapy, 32.8% (95% CI: 25.5–40.1) remained stable, and 18.1% (95% CI: 12.0–24.2) experienced a worsening of their condition. Although no major complications were observed, headaches 57.6 [37.9–77.3] and fever 53.1 [20.7–85.4] were commonly reported as minor adverse events. All of the results reported in this meta-analysis are consistent and credible according to the sensitivity analyses. Regardless of different individual studies, our meta-analysis provides a comprehensive overview showing the potential of MSC therapy as a possible effective treatment strategy for patients with MS.
format Online
Article
Text
id pubmed-10573670
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105736702023-10-14 Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis Islam, Md Asiful Alam, Sayeda Sadia Kundu, Shoumik Ahmed, Saleh Sultana, Shabiha Patar, Azim Hossan, Tareq J Clin Med Systematic Review The assurance of safety and effectiveness is a significant focal point in all therapeutic approaches. Although mesenchymal stem cells (MSCs) have been identified as a potential novel therapeutic strategy for multiple sclerosis (MS), existing evidence regarding the effectiveness and safety of this strategy remains inconclusive. Thus, the primary aim of this systematic review and meta-analysis (SRMA) was to comprehensively assess the effectiveness and safety of MSC therapy in individuals diagnosed with MS. A comprehensive search was conducted using appropriate keywords in the PubMed, Scopus, Cochrane, ScienceDirect, and Google Scholar databases to determine the eligible studies. The change in the expanded disability status scale (EDSS) score from baseline to follow-up was used to assess MSC efficacy. The effectiveness of the therapy was assessed using a random-effects model, which calculated the combined prevalence and 95% confidence intervals (CIs) for MS patients who experienced improvement, stability, or worsening of their condition. The protocol was registered in PROSPERO (CRD42020209671). The findings indicate that 40.4% (95% CI: 30.6–50.2) of MS patients exhibited improvements following MSC therapy, 32.8% (95% CI: 25.5–40.1) remained stable, and 18.1% (95% CI: 12.0–24.2) experienced a worsening of their condition. Although no major complications were observed, headaches 57.6 [37.9–77.3] and fever 53.1 [20.7–85.4] were commonly reported as minor adverse events. All of the results reported in this meta-analysis are consistent and credible according to the sensitivity analyses. Regardless of different individual studies, our meta-analysis provides a comprehensive overview showing the potential of MSC therapy as a possible effective treatment strategy for patients with MS. MDPI 2023-09-30 /pmc/articles/PMC10573670/ /pubmed/37834955 http://dx.doi.org/10.3390/jcm12196311 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Islam, Md Asiful
Alam, Sayeda Sadia
Kundu, Shoumik
Ahmed, Saleh
Sultana, Shabiha
Patar, Azim
Hossan, Tareq
Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis
title Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis
title_full Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis
title_fullStr Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis
title_full_unstemmed Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis
title_short Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis
title_sort mesenchymal stem cell therapy in multiple sclerosis: a systematic review and meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573670/
https://www.ncbi.nlm.nih.gov/pubmed/37834955
http://dx.doi.org/10.3390/jcm12196311
work_keys_str_mv AT islammdasiful mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis
AT alamsayedasadia mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis
AT kundushoumik mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis
AT ahmedsaleh mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis
AT sultanashabiha mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis
AT patarazim mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis
AT hossantareq mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis